We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Boehringer Ingelheim and DxS Sign Agreement to Identify EGFR Mutations in Patients with Lung Cancer
News

Boehringer Ingelheim and DxS Sign Agreement to Identify EGFR Mutations in Patients with Lung Cancer

Boehringer Ingelheim and DxS Sign Agreement to Identify EGFR Mutations in Patients with Lung Cancer
News

Boehringer Ingelheim and DxS Sign Agreement to Identify EGFR Mutations in Patients with Lung Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Boehringer Ingelheim and DxS Sign Agreement to Identify EGFR Mutations in Patients with Lung Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

DxS and Boehringer Ingelheim have entered into an agreement to provide a companion diagnostic test kit for Boehringer Ingelheim’s compound BIBW 2992 (Tovok™) to identify mutations of the EGFR (epidermal growth factor receptor) in patients with non small cell lung cancer. Financial terms of the agreement are not disclosed.

Clinical data published to date suggest that BIBW 2992 offers a marked increase in efficacy in comparison to standard treatments, for lung cancer patients carrying mutations in the EGFR gene. Under the terms of the agreement, DxS and Boehringer Ingelheim will work jointly to make a suitable companion diagnostic test kit globally available.

BIBW 2992 is a novel tyrosine kinase inhibitor that acts by irreversibly blocking the EGFR /HER2 receptors, which are promoters of tumor growth. As with other tyrosine kinase inhibitor therapies, patients with mutations in the EGFR gene will be more likely to respond to a medication that targets these receptors, thereby allowing doctors to prescribe the most effective and individual treatment.

Furthermore BIBW 2992 has demonstrated preclinical activity against erlotinib and gefitinib resistant mutations. With this approach, Boehringer Ingelheim is among the few companies advancing molecules of their pipeline within the area of personalized medicine.

The DxS EGFR companion diagnostic is a real-time PCR assay, designed to detect the most common mutations in the EGFR gene. The diagnostic has been developed and manufactured at DxS’ head office in Manchester, UK. and will be available later in the summer for Boehringer Ingelheim’s global, multi-centre Phase III clinical trial for BIBW 2992.

Commenting on this announcement, Dr Stephen Little, CEO of DxS says “This is another great endorsement of our companion diagnostic assays for predicting patient response to targeted therapies. It is an exciting step forward for personalized medicine and DxS is pleased to be at the forefront of this revolution in cancer treatment."
Advertisement